Skip to main content
. 2008 Jan 1;1(5):435–439.

Figure 2.

Figure 2

Endogenous biotin blocker (endogenous biotin blocking kit, Ventana Medical, Inc) has limited power in blocking EABA in renal neoplasms with high EB content. A pair of panels (objective magnification 4× and 40×) for each group are shown. With EB blocker, EABA was detected in 48% of oncocytomas (2A and 2B) and in 10% of papillary RCCs with G/E features (2C and 2D).